Evidence map›Paper›PMID 41901318›Full record

ArticlePharmaceuticals (Basel, Switzerland)2026

Synergistic Anti-Tumor Activity of LRPPRC Inhibition and Dasatinib Through Dual Oxidative Phosphorylation Disruption.

Jing Chen, Lu Gao, Yuxin Liang, Wei Zhou, Yong Wang, Xiaojia Wang, Xiaohong Fang, Xiying Shao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jing ChenThe Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou 310053, China.
Lu GaoHangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou 310018, China.ORCID 0009-0009-5139-260X
Yuxin LiangHangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou 310018, China.
Wei ZhouHangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou 310018, China.
Yong WangHangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou 310018, China.
Xiaojia WangThe Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou 310053, China.
Xiaohong FangHangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou 310018, China.
Xiying ShaoZhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou 310022, China.

Funding

Beijing Science and Technology Innovation Medical Development Foundation Grant No. KC2021-JX-0170-11Joint Innovation Fund (2025) of the Hangzhou Institute of Medicine, Chinese Academy of Sciences Grant No. 24CXJJ01Zhejiang Provincial Natural Science Foundation of China Grant No. TGD23H160004
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

combination therapyDasatinibhigh-throughput screeningLRPPRCsynergistic inhibition

Identifiers

PMID41901318
PMCPMC13029704

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.